Association of Type 2 Diabetes Mellitus with Dyslipidemia in Hypertensive Patients: A Retrospective Cross-Sectional Study
Objective: This study aimed to examine the association between type 2 diabetes mellitus (T2DM) and metabolic profile alterations—particularly dyslipidemia—in patients with hypertension, and to determine whether T2DM is independently associated with dyslipidemia in this population.
Methods: This retrospective cross-sectional study included 191 patients with a documented diagnosis of hypertension followed between September 1, 2024, and September 1, 2025. Participants were categorized according to T2DM status. Demographic, clinical, and laboratory data were retrieved from electronic medical records. Continuous variables are expressed as median (interquartile range) and categorical variables as counts and percentages. Group comparisons were performed using the Mann–Whitney U and chi-square tests. Associations between variables were evaluated using Spearman's rank correlation analysis, and factors independently associated with dyslipidemia were identified using binary logistic regression analysis.
Results: Participants had a median age of 50.0 (42.0–58.0) years; 66.0% were female and 24.1% had T2DM. Triglyceride levels were significantly higher in the T2DM group (P=0.039), as were C-reactive protein concentrations (P=0.025). Dyslipidemia was present in 56.5% of patients with T2DM compared with 13.8% of those without (P<0.001). In multivariable analysis, T2DM remained independently associated with dyslipidemia (odds ratio=4.47, 95% confidence interval: 1.58–12.67; P=0.005), as did age (odds ratio=1.038; P=0.049).
Conclusion: T2DM in hypertensive individuals was significantly and independently associated with dyslipidemia, most prominently reflected by elevated triglyceride levels. Lipid screening and cardiometabolic risk management should be approached more comprehensively in hypertensive patients with T2DM.
1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237. doi: 10.1038/s41581-019-0244-2.
2. Cosentino F, Grant PJ, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi: 10.1093/eurheartj/ehz486.
3. Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and Treatment of Dyslipidemia in Diabetes. Curr Cardiol Rep. 2021;23(4):26. doi: 10.1007/s11886-021-01455-w.
4. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-4806. doi: 10.1093/eurheartj/ehab551.
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421. doi: 10.1161/circ.106.25.3143.
6. Haq AU, Shahab K, Khattak IQ, et al. Comparison of lipid profiles and hypertension in type 2 diabetes mellitus patients with and without hypertension: a multicenter study. Int J Health Sci. 2023;6(S10):1298-1305. doi: 10.53730/ijhs.v6nS10.13949
7. Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192.
8. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480
9. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678
10. Reyes-Soffer G. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments. Curr Opin Endocrinol Diabetes Obes. 2021;28(2):85-89. doi: 10.1097/MED.0000000000000619
11. Gabani M, Shapiro MD, Toth PP. The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease. Eur Cardiol. 2023;18:e56. doi: 10.15420/ecr.2023.16.
12. Vergès B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886-899. doi: 10.1007/s00125-015-3525-8.
13. Martínez-Marroquín Y, Meaney A, Samaniego-Méndez V, et al. The TG/HDL-c lipid ratio as a cardiovascular risk marker in a Mexican urban middle-class population: do we need a risk score tailored for Mexicans? J Clin Med. 2023;12(18):6005. doi: 10.3390/jcm12186005
14. Feingold KR. Dyslipidemia in patients with diabetes. In: Feingold KR, Adler RA, Ahmed SF, et al., eds. Endotext [Internet]. South Dartmouth (MA): MDText.com Inc; 2000. Accessed February 27, 2026. Available at: https://www.ncbi.nlm.nih.gov/books/NBK305900/
15. Donath MY, Meier DT, Böni-Schnetzler M. Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease. Endocr Rev. 2019;40(4):1080-1091. doi: 10.1210/er.2019-00002.
16. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi: 10.2215/CJN.11491116.
17. Zhang H, Wang K, Zhao H, et al. Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions. Front Med (Lausanne). 2025;12:1631053. doi: 10.3389/fmed.2025.1631053.
18. Tsao CW, Aday AW, Almarzooq ZI, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93-e621. doi: 10.1161/CIR.0000000000001123.
19. Visseren FLJ, Mach F, Smulders YM, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
Copyright (c) 2026 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Article Information
- Article Type Research Article
- Submitted April 17, 2026
- Accepted May 31, 2026
- Published August 1, 2026
- Issue Forthcoming Issue: Vol. 12 Iss. 8 (August 2026)
- Section Research Article
- Categories
The data supporting the findings of this study are not publicly available due to institutional and ethical restrictions. The data were obtained from hospital electronic medical records and analyzed in anonymized form. Access may be considered upon reasonable request to the corresponding author, subject to approval by the hospital administration.
